Reduced lung function in smokers in a lung cancer screening cohort with asbestos exposure and pleural plaques

2016 ◽  
Vol 59 (3) ◽  
pp. 178-185 ◽  
Author(s):  
Sarah Lopatin ◽  
Jun-Chieh Tsay ◽  
Doreen Addrizzo-Harris ◽  
John S. Munger ◽  
Harvey Pass ◽  
...  
2016 ◽  
Vol 59 (5) ◽  
pp. 424-424 ◽  
Author(s):  
Sarah Lopatin ◽  
Jun-Chieh Tsay ◽  
Doreen Addrizzo-Harris ◽  
John S. Munger ◽  
Harvey Pass ◽  
...  

CHEST Journal ◽  
2017 ◽  
Vol 152 (4) ◽  
pp. A827
Author(s):  
Nicholas Stickel ◽  
Papia Sen ◽  
Christian Kyung ◽  
Abhijit Mahalingashetty ◽  
Michael Cutaia ◽  
...  

2018 ◽  
Vol 27 (4) ◽  
pp. 289-295 ◽  
Author(s):  
Ugo Pastorino ◽  
Daniele Morelli ◽  
Alfonso Marchianò ◽  
Stefano Sestini ◽  
Paola Suatoni ◽  
...  

CHEST Journal ◽  
2020 ◽  
Author(s):  
Robert P. Young ◽  
Raewyn J. Hopkins ◽  
Greg D. Gamble ◽  
Gerard A. Silvestri

BMC Cancer ◽  
2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Laurie Grieshober ◽  
Stefan Graw ◽  
Matt J. Barnett ◽  
Mark D. Thornquist ◽  
Gary E. Goodman ◽  
...  

Abstract Background A low level of methylation at cg05575921 in the aryl-hydrocarbon receptor repressor (AHRR) gene is robustly associated with smoking, and some studies have observed associations between cg05575921 methylation and increased lung cancer risk and mortality. To prospectively examine whether decreased methylation at cg05575921 may identify high risk subpopulations for lung cancer screening among heavy smokers, and mortality in cases, we evaluated associations between cg05575921 methylation and lung cancer risk and mortality, by histotype, in heavy smokers. Methods The β-Carotene and Retinol Efficacy Trial (CARET) included enrollees ages 45–69 with ≥ 20 pack-year smoking histories and/or occupational asbestos exposure. A subset of CARET participants had cg05575921 methylation available from HumanMethylationEPIC assays of blood collected on average 4.3 years prior to lung cancer diagnosis in cases. Cg05575921 methylation β-values were treated continuously for a 10% methylation decrease and as quintiles, where quintile 1 (Q1, referent) represents high methylation and Q5, low methylation. We used conditional logistic regression models to examine lung cancer risk overall and by histotype in a nested case-control study including 316 lung cancer cases (diagnosed through 2005) and 316 lung cancer-free controls matched on age (±5 years), sex, race/ethnicity, enrollment year, current/former smoking, asbestos exposure, and follow-up time. Mortality analyses included 372 lung cancer cases diagnosed between 1985 and 2013 with available methylation data. We used Cox proportional hazards models to examine mortality overall and by histotype. Results Decreased cg05575921 methylation was strongly associated with smoking, even in our population of heavy smokers. We did not observe associations between decreased pre-diagnosis cg05575921 methylation and increased lung cancer risk, overall or by histotype. We observed linear increasing trends for lung cancer-specific mortality across decreasing cg05575921 methylation quintiles for adenocarcinoma and small cell carcinoma (P-trends = 0.01 and 0.04, respectively). Conclusions In our study of heavy smokers, decreased cg05575921 methylation was strongly associated with smoking but not increased lung cancer risk. The observed association between cg05575921 methylation and increased mortality in adenocarcinoma and small cell histotypes requires further examination. Our results do not support using decreased cg05575921 methylation as a biomarker for lung cancer screening risk stratification.


2017 ◽  
Vol 17 (1) ◽  
Author(s):  
Mario Silva ◽  
Nicola Sverzellati ◽  
Davide Colombi ◽  
Gianluca Milanese ◽  
Carlo La Vecchia ◽  
...  

Thorax ◽  
2019 ◽  
Vol 74 (8) ◽  
pp. 761-767 ◽  
Author(s):  
Michael W Marcus ◽  
Stephen W Duffy ◽  
Anand Devaraj ◽  
Beverley A Green ◽  
Matthijs Oudkerk ◽  
...  

BackgroundEstimation of the clinical probability of malignancy in patients with pulmonary nodules will facilitate early diagnosis, determine optimum patient management strategies and reduce overall costs.MethodsData from the UK Lung Cancer Screening trial were analysed. Multivariable logistic regression models were used to identify independent predictors and to develop a parsimonious model to estimate the probability of lung cancer in lung nodules detected at baseline and at 3-month and 12-month repeat screening.ResultsOf 1994 participants who underwent CT scan, 1013 participants had a total of 5063 lung nodules and 52 (2.6%) of the participants developed lung cancer during a median follow-up of 4 years. Covariates that predict lung cancer in our model included female gender, asthma, bronchitis, asbestos exposure, history of cancer, early and late onset of family history of lung cancer, smoking duration, FVC, nodule type (pure ground-glass and part-solid) and volume as measured by semiautomated volumetry. The final model incorporating all predictors had excellent discrimination: area under the receiver operating characteristic curve (AUC 0.885, 95% CI 0.880 to 0.889). Internal validation suggested that the model will discriminate well when applied to new data (optimism-corrected AUC 0.882, 95% CI 0.848 to 0.907). The risk model had a good calibration (goodness-of-fit χ[8] 8.13, p=0.42).ConclusionsOur model may be used in estimating the probability of lung cancer in nodules detected at baseline and at 3 months and 12 months from baseline, allowing more efficient stratification of follow-up in population-based lung cancer screening programmes.Trial registration number78513845.


Sign in / Sign up

Export Citation Format

Share Document